Search clinical trials for: VNRX-5024

Total 227 results

Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5024 Safety and PK in Healthy Adult Volunteers

Healthy Subjects

Netherlands
Venatorx Pharmaceuticals, Inc.
National Institutes of Health (NIH)

Completed

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

Pharmacokinetics

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers

Healthy Subjects

Netherlands
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

Bacterial Infections

United States
Venatorx Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Terminated

VNRX-9945 Safety and Pharmacokinetics in Healthy Adult Volunteers

Healthy Volunteers

New Zealand
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

Healthy Volunteers

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

Bacterial Infections

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants

Pharmacokinetics

United States
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

Pharmacokinetics

United States
Venatorx Pharmaceuticals, Inc.
National Institutes of Health (NIH)

Completed

Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

Healthy Subjects

United States
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
Neurocrine Biosciences

Completed

A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Spain, Finland, Canada, France, Czech Republic, Germany, South Africa, United Kingdom
KBP Biosciences
Worldwide Clinical Trials

Completed

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease (BLOCKCKD)

Hypertension | Chronic Kidney Diseases

United States
KBP Biosciences
Covance

Completed

Mass Balance Study of KBP-5074 in Healthy Male Subjects

Healthy

United States
KBP Biosciences

Completed

Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074

Healthy
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
University of Southern California

Terminated

Oral NRX 194204 in Patients With Refractory Malignancies

Refractory Malignancies

United States
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

China
Zhuhai Yufan Biotechnologies Co., Ltd

Recruiting

A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor | Advanced Solid Malignancies

United States
Venatorx Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections (CERTAIN-1)

Urinary Tract Infections | Acute Pyelonephritis

United States, Argentina, Brazil, Bulgaria, China, Croatia, Hungary, Latvia, Mexico, Peru, Romania, Russian Federation, Serbia, Turkey, Ukraine
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

Advanced Solid Tumor

China
NorthSea Therapeutics B.V.

Completed

A Phase 1, First Time in Humans Study of NST-1024

Hypertriglyceridemia

United Kingdom
Dong-A ST Co., Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of DA-5204

Acute Gastritis | Chronic Gastritis

Korea, Republic of
Asmacure Ltée

Completed

Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma

Asthma

Canada
CERESPIR

Completed

Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects (CT03)

Alzheimer's Disease

United States
Bayer

Completed

Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea

Contraception

Korea, Republic of
Viome

Completed

Efficacy of VRx MyBiotics Oral Lozenges

Oral Microbiome Health

United States
Infinity Pharmaceuticals, Inc.

Withdrawn

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Hepatic Impairment | Non-alcoholic Steatohepatitis

United States
Bayer

Completed

Wellnara Post-marketing Surveillance in Japan (WELLNARA)

Osteoporosis, Postmenopausal

Japan
Amicus Therapeutics

Active, not recruiting

Gene Therapy for Children With CLN3 Batten Disease

Batten Disease | CLN3

United States
Infinity Pharmaceuticals, Inc.

Terminated

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Infinity Pharmaceuticals, Inc.

Completed

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
Vestre VikenHF Kongsberg Sykehus
Norwegian Medical Association

Completed

Efficacy Side-effect Score (ESS): Development and Evaluation of a New Tool for Patients After Surgery (ESScore)

Postoperative Complications | Postoperative Pain | Postoperative Vomiting and Nausea | Mental Status Changes Postoperative

Kazakhstan, Russian Federation
Merck Sharp & Dohme LLC

Completed

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Rosacea
Massachusetts General Hospital
Dana-Farber Cancer Institute; Infinity Pharmaceuticals, Inc.

Terminated

IPI-504 in NSCLC Patients With ALK Translocations

Lung Cancer | Stage IV Lung Cancer | Stage IIIb Lung Cancer

United States
Asmacure Ltée

Terminated

Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate Asthma

Asthma

Canada
Infinity Pharmaceuticals, Inc.

Completed

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Gastrointestinal Stromal Tumors | Soft Tissue Sarcomas

United States, Canada
Orum Therapeutics USA, Inc.

Recruiting

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

United States
OPKO Health, Inc.

Completed

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

Hemophilia A | Hemophilia B

United States
Hutchison Medipharma Limited

Recruiting

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Gastric Cancer | Esophagogastric Junction Disorder

China
Hutchison Medipharma Limited
Monash University; Sir Charles Gairdner Hospital; Austin Hospital, Melbourne...

Completed

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors (HMPL-504)

Tumor

Australia
Artax Biopharma Inc
Simbec Research

Completed

Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects

Healthy

United Kingdom
Asmacure Ltée

Completed

Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)

COPD

Canada
GTx

Completed

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

Cachexia

United States, Canada
Asmacure Ltée

Completed

Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma

Mild Allergic Asthma

Canada
KBP Biosciences

Active, not recruiting

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe CKD (Clarion-CKD)

Chronic Kidney Diseases

China, Spain, Australia, Hungary, Malaysia, United States, Germany, Bulgaria, Serbia, Hong Kong, Georgia, Bosnia and Herzegovina, Croatia, Czechia, South Africa, Canada, Israel, Korea, Republic of, Latvia, Lithuania, Poland, Taiwan
Hutchison Medipharma Limited

Active, not recruiting

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Lung Sarcomatoid Carcinoma

China

Search clinical trials for: VNRX-5024

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations